Cardiff Oncology, Inc.(NASDAQ : CRDF)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Services » Medical Or Nursing Services
|GH||Guardant Health, Inc.||-0.32%||109.80||0.0%||$83.00m|
|FLGT||Fulgent Genetics, Inc.||0.36%||92.25||0.6%||$62.73m|
|OSH||Oak Street Health, Inc.||0.32%||63.08||0.0%||$48.72m|
|LHCG||LHC Group, Inc.||1.34%||215.18||2.9%||$31.94m|
|ONEM||1Life Healthcare, Inc.||0.11%||27.04||0.0%||$26.61m|
|ACHC||Acadia Healthcare Co., Inc.||0.08%||61.72||26.9%||$21.49m|
|CANO||Cano Health, Inc.||0.09%||10.73||0.0%||$19.00m|
|OPCH||Option Care Health, Inc.||-0.29%||20.72||0.0%||$13.59m|
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.